OUR PRODUCT

XEOMIN® (Botulinum toxin type A)

CLICK HERE FOR SmPC >

Our Product

XEOMIN® (Botulinum toxin type A)
CLICK HERE FOR SmPC >

ADVERSE EVENTS REPORTING

Merz Therapeutics has a strong commitment to patient safety. We encourage all healthcare professionals and patients to report information about the safety of our products; this includes any adverse events and product complaints.

If you are a patient taking or using a Merz Therapeutics product and are experiencing any side effects, talk immediately to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

Adverse events should also be reported:

directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ (United Kingdom),

or at https://www.hpra.ie/homepage/about-us/report-an-issue (Republic of Ireland)

Adverse events should also be reported to Merz Pharma UK Ltd:

• by email to UKdrugsafety@merz.com,
• via phone on 0333 200 4143
• or contact us here

By reporting adverse events you can help provide more information on the safety of our products.